Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF

Bibliography

• Mitsuya H, Weinhold KJ, Furman PA, 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82(20):7096-100
   PubMed Web of Science ®Google Scholar
• De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 2009;19(5):287-99
   PubMedGoogle Scholar
• Marchand C. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet. Expert Opin Investig Drugs 2012; Epub ahead of print
   PubMedGoogle Scholar
• Staszewski S, Keiser P, Montaner J, Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001;285(9):1155-63
   PubMed Web of Science ®Google Scholar
• Matheron S, Descamps D, Boue F, Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003;8(2):163-71
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-61
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-240. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 10 May 2012]
   Google Scholar
• Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. Cochrane Database Syst Rev 2009(3):CD005481
   Google Scholar
• Smith KY, Patel P, Fine D, Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23(12):1547-56
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, Superior outcome for tenofovir DF (RDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients [abstract no. WeOa0202]. The 3rd IAS Conference on HIV Pathogenesis and Treatment; 24 – 27 July 2005; Rio de Janeiro, Brazil
   Google Scholar
• Gallant JE, DeJesus E, Arribas JR, Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354(3):251-60
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998;12(9):1112-13
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Lou Y, Thompson NF, Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 2001;41(3):277-88
   PubMed Web of Science ®Google Scholar
• Mathias AA, Hinkle J, Menning M, Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007;46(2):167-73
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010;4:115-25
   PubMed Web of Science ®Google Scholar
• Maitland D, Jackson A, Osorio J, Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008;9(8):667-72
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185(9):1251-60
   PubMed Web of Science ®Google Scholar
• Dejesus E, Young B, Morales-Ramirez JO, Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51(2):163-74
   PubMed Web of Science ®Google Scholar
• Hodder SL, Mounzer K, Dejesus E, Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010;24(2):87-96
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010;24(18):2835-40
   PubMed Web of Science ®Google Scholar
• Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 2012;7(2):e31591
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P, Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304(3):321-33
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-40
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378(9787):229-37
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378(9787):238-46
   PubMed Web of Science ®Google Scholar
• Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet 2011;378(9787):201-3
   PubMed Web of Science ®Google Scholar
• Wheeler WH, Ziebell RA, Zabina H, Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24(8):1203-12
   PubMed Web of Science ®Google Scholar
• Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64(5):910-28
   PubMed Web of Science ®Google Scholar
• Cohen C, Molina J, Cahn P, Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012;60(1):33-42
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Approval of Edurant (rilpivirine) a new NNRTI for the treatment of HIV in treatment naive patients. 2011. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm256151.htm [Accessed 10 May 2012]
   Google Scholar
• Mathias AA, German P, Murray BP, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87(3):322-9
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Rockstroh JK, Reynes J, Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43(1):1-5
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Berger DS, Lampiris H, Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010;201(6):814-22
   PubMed Web of Science ®Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
   PubMed Web of Science ®Google Scholar
• Desimmie BA, Schrijvers R, Debyser Z. Elvitegravir: a once daily alternative to raltegravir. Lancet Infect Dis 2012;12(1):3-5
   PubMedGoogle Scholar
• German P, Mathias A, Wei L, Cytochrome P450 2D6, 2B6 abd O-glycoprotein using phenotypic probes [abstract O_01]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 – 15 April 2011; Miami, USA
   Google Scholar
• Ramanathan S, Wang H, Stondell T, Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin or rifabutin [abstract O_03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011;50(4):229-44
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P, Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25(6):F7-12
   PubMed Web of Science ®Google Scholar
• Elion R, Gathe J, Rashbaum B, Single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; "QUAD") maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks [abstract H-938B]. 50th Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2010; Boston, USA
   Google Scholar
• Sax P, DeJesus E, Mills A, Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects [abstract 101]. 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Food and Drug Administration/CDER Web site. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. 2002. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf [Accessed 10 May 2012]
   Google Scholar
• DeJesus E, Rockstroh J, Henry K, Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naive HIV-1+ subjects showing efficacy, safety, and pharmacokinetics [abstract 627]. 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Wei X, Szwarcberg J, Exposure/Response Analysis of Once-daily Elvitegravir Administered as Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Single-tablet Regimen in HIV-1+ Patients [abstract 622]. 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Lepist E, Murray B, Tong L, Effect of Cobicistat and Ritonavir on Proximal Renal Tubular Cell Uptake and Efflux Transporters [abstract A1-1724]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2011; Chicago, USA
   Google Scholar
• Elion R, Cohen C, Gathe J, Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011;25(15):1881-6
   PubMed Web of Science ®Google Scholar
• German P, Lui C, Warren D, Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function [abstract H2-804]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2011; Chicago, USA
   Google Scholar
• Cooper RD, Wiebe N, Smith N, Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51(5):496-505
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JD, Henry K, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439-48
   PubMed Web of Science ®Google Scholar
• Schrijvers R, Debyser Z. Quad's in it for antiretroviral therapy? Lancet 2012;379(9835):2403-5
   PubMedGoogle Scholar
• Antiviral Drugs Advisory Committee Meeting Briefing Document (Gilead Sciences). Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (EVG/COBI/FTC/TDF, Quad STR) for treatment of HIV-1 infection in adults. 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM303397.pdf [Accessed 11 May 2012]
   Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2011;12(1):27-35
   PubMedGoogle Scholar
• McColl D, Fransen S, Gupta S, Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 2007;12(Suppl 1):S11
   Google Scholar
• Waters J, Margot N, Hluhanich RM, Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [abstract 16]. Antivir Ther 2009;14(Suppl 1):A137
   Google Scholar
• Mukherjee R, Jensen ST, Male F, Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 2011;25(16):1951-9
   PubMedGoogle Scholar
• Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009;83(19):10245-9
   PubMedGoogle Scholar
• Shimura K, Kodama E, Sakagami Y, Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008;82(2):764-74
   PubMed Web of Science ®Google Scholar
• Margot NA, Hluhanich RM, Jones GS, In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2011;93(2):288-96
   PubMedGoogle Scholar
• Goethals O, Clayton R, Van Ginderen M, Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82(21):10366-74
   PubMed Web of Science ®Google Scholar
• Kodama E, Shimura K, Sakagami I, In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137 [abstract H-254]. 46th Interscience conference on antimicrobial agents and chemotherapy (ICAAC); 27 – 30 September 2006; San Francisco, USA
   Google Scholar
• Jones GS, Yu F, Zeynalzadegan A, Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009;53(3):1194-203
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-65
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17(5):138-45
   PubMedGoogle Scholar
• Blanco JL, Varghese V, Rhee SY, HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011;203(9):1204-14
   PubMed Web of Science ®Google Scholar
• Metifiot M, Vandegraaff N, Maddali K, Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011;25(9):1175-8
   PubMed Web of Science ®Google Scholar
• Reigadas S, Anies G, Masquelier B, The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS ONE 2010;5(4):e10311
   Google Scholar
• Garrido C, Villacian J, Zahonero N, Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012;56(6):2873-8
   PubMed Web of Science ®Google Scholar
• Garrido C, Villacian J, Zahonero N, Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Soriano V, Cox J, Eron J. Dolutegravir (DTG, S/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 in the VIKING Study [Number PS1/2]. 13th EACS; 12 – 15 October 2011; Belgrade, Serbia
   Google Scholar
• Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012;21(4):523-30
   PubMed Web of Science ®Google Scholar
• Garrido C, de Mendoza C, Alvarez E, Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses 2011;28(2):156-64
   PubMedGoogle Scholar
• Kawaguchi I, Ishikawa T, Ishibashi M, Gilead integrase inhibitor: safety and pharmacokinetics of single oral dose of JTK 303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers [abstract no. 580]. 13th conference on retroviruses and opportunistic infections; 5 – 8 February 2006; Denver, USA
   Google Scholar
• Ramanathan S, Wright M, West S, Pharmacokinetics, metabolism, and excretion of ritonavir-boosted GS-9137 (Elvitegravir) [abstract 30]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2007; Budapest, Hungary
   Google Scholar
• German P, Warren D, West S, Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55(3):323-9
   PubMed Web of Science ®Google Scholar
• Mathias A, Koziara J, Wei L, Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P 13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 – 15 April 2011; Miami, USA
   Google Scholar
• Acosta EP, Kendall MA, Gerber JG, Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007;51(9):3104-10
   PubMedGoogle Scholar
• German P, Wang M, Warren D, Kearney BP. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and EVG/COBI/FTC/TDF single tablet regimen [abstract O_17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13 – 15 April 2011; Miami, USA
   Google Scholar
• Ramanathan S, Shen G, Hinkle J, Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007;46(2):160-6
   PubMedGoogle Scholar
• Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007;45(3):274-9
   PubMedGoogle Scholar
• Mathias AA, Hinkle J, Shen G, Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 2008;49(2):156-62
   PubMedGoogle Scholar
• Ramanathan S, Kakuda TN, Mack R, Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13(8):1011-17
   PubMedGoogle Scholar
• Mathias A, West S, Enejosa J, Kearney B. A pharmacokinetic interaction between lopinavir/r and elvitegravir [abstract A-1418]. 47th Interscience conference on antimicrobial agents and chemotherapy; 17 – 20 September 2007; Chicago, USA
   Google Scholar
• Ramanathan S, Mathias A, Hinkle J, Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir [abstract O18]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7 – 9 April 2008; New Orleans, USA
   Google Scholar
• Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85(1):64-70
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias A, Shen G, Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract WEPEB014]. 4th International conference on HIV pathogenesis, treatment and prevention; 22 – 25 July 2007; Sydney, Australia
   Google Scholar
• Ramanathan S, Abel S, Tweedy S, Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 2009;53(2):209-14
   Google Scholar
• Ramanathan S, Wang H, Custodio J, Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla) in healthy subjects [abstract O_21]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Ruane P, DeJesus E, Berger D, GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients [abstract 103]. 19th Conference on Retroviruses and Opportunistic Infections; 5 – 8 March 2012; Seattle, USA
   Google Scholar
• Ramanathan S, Wei X, Custodio J, Pharmacokinetics of a novel EVG/COBI/FTV/GS-7340 single tablet regimen [abstract O_13]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 – 18 April 2012; Barcelona, Spain
   Google Scholar
• Eron JJ, Young B, Cooper DA, Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Christ F, Voet A, Marchand A, Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6(6):442-8
   PubMed Web of Science ®Google Scholar
• Ray AS, Cihlar T, Robinson KL, Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011:354908. [Epub 2011 Jun 7]
   PubMedGoogle Scholar